← Leaderboards
Wells A Messersmith
Johns Hopkins University
$5,466,310
Attributed
$14,486,293
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,486,293 · 6
By mechanism
UM1$11,127,273 · 1
R01$1,482,568 · 1
R21$1,183,054 · 2
K23$693,360 · 1
M01$38 · 1
Top collaborators
- Michael A. Carducci4 shared
- Ryan Gentzler4 shared
- Glenn Liu4 shared
- Jimmy Ruiz3 shared
- Jan Hendrik Beumer2 shared
- Michelle A Rudek1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Karen L. Beemon$8,952,439
- Michael A. Carducci$23,642,506
- Mark Donowitz$42,405,980
- Philip A Cole$22,629,551
- Seema Khurana$9,386,019
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientDesignResponsePharmacodynamicsToxic EffectClinical TrialsBiologicalSignal TransductionBiopsyEvaluationTumor TissuePrincipal InvestigatorGrantPathway InteractionsTumorCancer EtiologyCessation Of LifeBasePharmaceutical PreparationsInhibitor/AntagonistLaboratoriesMalignant NeoplasmsColorectal CancerImage
Grant awards (20)
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,817,609
UM1 · FY2025 · CA
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,727,315
UM1 · FY2024 · CA
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,836,359
UM1 · FY2023 · CA
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$5,745,990
UM1 · FY2020 · CA
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients$298,713
R01 · FY2014 · CA · contact PI
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients$289,474
R01 · FY2013 · CA · contact PI
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients$307,951
R01 · FY2012 · CA · contact PI
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients$288,750
R01 · FY2011 · CA · contact PI
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients$297,680
R01 · FY2010 · CA · contact PI
Evaluation of Src Inhibition in Pancreas Cancer$314,341
R21 · FY2009 · CA · contact PI
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer$137,700
K23 · FY2009 · CA · contact PI
Evaluation of Src Inhibition in Pancreas Cancer$295,988
R21 · FY2008 · CA · contact PI
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer$137,700
K23 · FY2008 · CA · contact PI
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer$246,308
R21 · FY2007 · CA · contact PI
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer$137,700
K23 · FY2007 · CA · contact PI
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer$36,278
R21 · FY2007 · CA · contact PI
BAY 43-9006 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN$38
M01 · FY2007 · RR · contact PI
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer$290,139
R21 · FY2006 · CA · contact PI
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer$140,130
K23 · FY2006 · CA · contact PI
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer$140,130
K23 · FY2005 · CA